Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 184 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Xerostomia Clear all
Terminated Phase 2 Interventional Results available

Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia

NCT00503776
View directory record Official record
Conditions
Dysphagia, Head and Neck Cancer, Mucositis, Xerostomia
Interventions
exercise intervention, amifostine trihydrate, therapeutic dietary intervention
Behavioral · Drug · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 2 Interventional

Pilot Study of Thalidomide to Treat Sjogren's Syndrome

NCT00001599
View directory record Official record
Conditions
Sjogren's Syndrome, Xerostomia
Interventions
Thalidomide
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

NCT04129164
View directory record Official record
Conditions
Sjögren's Syndrome
Interventions
VIB4920, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Fullerton, California • Upland, California • Lawrenceville, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

TrueTear in Sjogren's Disease Patients

NCT03719885
View directory record Official record
Conditions
Dry Eye Syndromes, Sjogren's Syndrome
Interventions
TrueTear Intranasal Tear Neurostimulator
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 4, 2026, 1:48 PM EDT
Recruiting Phase 1 Interventional

d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC

NCT04392622
View directory record Official record
Conditions
Xerostomia
Interventions
D-Limonene Gelcaps, Intensity modulated radiotherapy (IMRT), Cisplatin, Xerostomia questionnaire
Drug · Radiation · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Evaluation of MucoPEG™ for Xerostomia

NCT04986501
View directory record Official record
Conditions
Dry Mouth, Xerostomia
Interventions
MucoPEG, Biotene
Device
Lead sponsor
SunBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Colorado Springs, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Not applicable Interventional Results available

Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer

NCT01748942
View directory record Official record
Conditions
Dysphagia, Pain, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma
Interventions
Dexamethasone, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Transoral Robotic Surgery
Drug · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 4, 2026, 1:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Research Registry for Neonatal Lupus

NCT00074373
View directory record Official record
Conditions
Neonatal Lupus, Systemic Lupus Erythematosus, Sjogren's Syndrome, Congenital Heart Block
Interventions
No intervention; observational
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Sep 4, 2026, 1:48 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Raptiva to Treat Sjogren's Syndrome

NCT00344448
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Raptiva
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Sep 4, 2026, 1:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Differential Diagnosis of Sjögren's Versus Non-Sjögren's Dry Eye

NCT04493658
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye Syndromes, Ocular Surface Disease, Sjogren's Syndrome
Interventions
Questionnaires, Tear fluid sampling, Impression Cytology
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome

NCT00852839
View directory record Official record
Conditions
Dry Mouth Associated With Sjogren's Syndrome, Xerostomia
Interventions
Placebo, 552-02
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
15
States / cities
Trumbull, Connecticut • Gainesville, Florida • Indianapolis, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Xylitol Disk Use in Adults With Dry Mouth

NCT01823445
View directory record Official record
Conditions
Mutans Streptococci, Xerostomia
Interventions
Xylitol disk
Other
Lead sponsor
University of Washington
Other
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optical Sensor for Photodynamic Detection of Oral Pathology

NCT00540774
View directory record Official record
Conditions
Mouth Diseases
Interventions
detection of oral pathology
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
1,004 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2026
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Active, not recruiting Phase 3 Interventional

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214
View directory record Official record
Conditions
Sjogren Syndrome
Interventions
VAY736, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
23
States / cities
Fullerton, California • La Palma, California • Brandon, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Active, not recruiting Phase 3 Interventional

Dry Mouth Toothpaste Study - Comparing Two Toothpastes With Arginine

NCT06365047
View directory record Official record
Conditions
Xerostomia
Interventions
8% Arginine toothpaste, 1000 ppm F toothpaste
Device · Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Completed No phase listed Observational

Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells

NCT00023491
View directory record Official record
Conditions
Graft vs Host Disease, Sjogren's Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 4, 2026, 1:48 PM EDT
Active, not recruiting Not applicable Interventional

Effect of Whitening Agent With Emulsion Gel in Saliva and Halitosis

NCT06194123
View directory record Official record
Conditions
Xerostomia, Halitosis
Interventions
Crest Daily Whitening Serum
Other
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

NCT03905525
View directory record Official record
Conditions
Sjögren Syndrome
Interventions
CFZ533, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Suwanee, Georgia • Indianapolis, Indiana • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)

NCT04572841
View directory record Official record
Conditions
Sjögren's Syndrome, Sjogren's Syndrome
Interventions
SAR441344, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
DeBary, Florida • Duncansville, Pennsylvania • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 1 Interventional

Fecal Microbial Transplant (FMT) for Sjogrens Syndrome

NCT03926286
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
FMP-30
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Sep 4, 2026, 1:48 PM EDT
Terminated Phase 2 Interventional Results available

Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects

NCT01316770
View directory record Official record
Conditions
Sjögren's Syndrome, Xerostomia
Interventions
Dexamethasone Parotid Irrigation, Placebo Parotid Irrigation
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions

NCT01903109
View directory record Official record
Conditions
Dry Mouth
Interventions
Cevimeline
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 4, 2026, 1:48 PM EDT
Recruiting Phase 2 Interventional

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease

NCT07281456
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Tofacitinib
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome

NCT04541589
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Iscalimab, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Suwanee, Georgia • Baton Rouge, Louisiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 4, 2026, 1:48 PM EDT